✦ LIBER ✦

Toxicity profiles of HER2/ neu peptide anticancer vaccines: the picture from Phase/I and II clinical trials

✍ Scribed by Baxevanis, Constantin N; Papamichail, Michael; Perez, Sonia A

Book ID: 120628068
Publisher: Expert Reviews
Year: 2012
Tongue: English
Weight: 795 KB
Volume: 11
Category: Article
ISSN: 1476-0584
DOI: 10.1586/erv.12.33

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and Immunologic Responses of HL

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

✍ Ritesh Patil; Guy T. Clifton; Jarrod P. Holmes; Asna Amin; Mark G. Carmichael; J 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 728 KB

Early results of a phase I clinical tria

Early results of a phase I clinical trial of an Ii-Key/HER2/neu MHC Class II peptide-based vaccine in breast cancer patients

✍ Steven Khoo; Catherine Storrer; Katie Harris; Yusuf Jama; Anna Smith; Zia Dehqan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 47 KB

950 RESULTS FROM THE FIRST PHASE I CLINI

950 RESULTS FROM THE FIRST PHASE I CLINICAL STUDY OF THE NOVEL II-KEY/HER-2/NEU (776–790) HYBRID PEPTIDE VACCINE IN PATIENTS WITH PROSTATE CANCER

✍ S. Mpisias; T. Karaolides; A. Pappas; E. Koutsiaris; A. Konandreas; S. Perez; V. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Immunological monitoring of in vitro and

Immunological monitoring of in vitro and in vivo immune responses to the Ii-Key/HER2/neu MHC class II peptide vaccine in a phase I clinical trial in breast cancer patients

✍ S. Khoo; C.E. Storrer; K.A. Harris; Y.H. Jama; Z.A. Dehqanzada; C.D. Shriver; E. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Results of the first phase 1 clinical tr

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients : United States Military Cancer Institute Clinical Trials Group Study I-04

✍ Mark G. Carmichael; Linda C. Benavides; Jarrod P. Holmes; Jeremy D. Gates; Eliza 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Optimal dose and schedule of an HER-2/ne

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

✍ Jarrod P. Holmes; Jeremy D. Gates; Linda C. Benavides; Matthew T. Hueman; Mark G 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB